HOME >> MEDICINE >> NEWS
Statin therapy cost-effective for a wider range of individuals

Statin therapy is cost-effective for a wider range of individuals with vascular disease or diabetes than previously recognised, concludes a study published online today (Thursday May 12, 2005) by THE LANCET.

Current guidelines generally recommend the initiation of statin therapy when the estimated 10-year risk of a non-fatal heart attack or coronary death is at least 15-20%.

The Heart Protection Study (HPS) has previously shown that lowering cholesterol concentrations with 40mg of simvastatin daily produces substantial reductions not just in the rates of such coronary events, but also in the rates of strokes and revascularisation procedures among a wide-range of high-risk individuals, irrespective of their pre-treatment blood cholesterol concentrations. In the HPS, over 20,500 adults aged 40-80 years with vascular disease or diabetes were randomly assigned to 40mg of simvastatin daily or a placebo. In the latest study the HPS researchers compared the costs of hospitalisations and statin therapy between the two groups, and estimated the cost-effectiveness for participants with varying levels of vascular disease risk.

They found a 22% relative reduction in the costs of hospitalisations for vascular events in the statin group, with similar proportional reductions in every sub-category of patients studied. Overall, the cost of avoiding a major vascular event was estimated to be 11,600, but there was substantial variation between the risk subgroups. For example, among individuals with a 42% 5-year risk of a major vascular event, the estimated cost-effectiveness was 4,500 per major vascular event avoided. By contrast, among those with a 12% 5-year risk, it was estimated to be 31,100. The authors believe that initiation of statin therapy should now be considered for people at lower risk for coronary or other major vascular events than is currently recommended.

Professor Rory Collins (Clinical Trial Service Unit, University of Oxford, UK), p
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
11-May-2005


Page: 1 2

Related medicine news :

1. Statin drugs may delay progressive artery damage in children
2. Statin use linked with decreased prostate cancer mortality rates, lower PSA levels
3. Statins linked to lower risk of infection
4. Statin users risk heart attacks by dropping treatment or taking low doses
5. Statins protect smokers from lung damage
6. Statins reduce risk of stroke in heart patients
7. Statin use associated with reduced risk of common type of cataract
8. Statins prove life-saving in patients with acute coronary syndromes
9. Statins may improve circulation in the retina
10. Statins, beta-blockers lessen heart attack risk, says Stanford-Kaiser study
11. Statins have neutral effect on risk of cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
Cached News: